Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Add To Watchlist

Recent & Breaking News (OTCPK:AZNCF)

A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Benzinga.com August 8, 2017

Acalabrutinib Granted Breakthrough Therapy Designation by US FDA for the Treatment of Patients with Mantle Cell Lymphoma

Business Wire August 1, 2017

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer

Business Wire July 31, 2017

Why Is AstraZeneca Sinking Today?

Benzinga.com July 27, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com July 27, 2017

TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival in the Phase III FLAURA Trial for Lung Cancer

Business Wire July 27, 2017

Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

PR Newswire July 27, 2017

The Market In 5 Minutes

Benzinga.com July 14, 2017

Analyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva

Benzinga.com July 13, 2017

Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi

PR Newswire July 5, 2017

Watch These 7 Huge Put Purchases In Wednesday Trade

Benzinga.com June 28, 2017

Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Benzinga.com June 22, 2017

AstraZeneca Presents New Data Underpinning Safety Profile and Real-World CV Outcomes of Farxiga at ADA 2017

Business Wire June 12, 2017

AstraZeneca to Present Scientific Advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

Business Wire June 8, 2017

AstraZeneca Presents Tagrisso® (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases

Business Wire June 6, 2017

LYNPARZA™ (olaparib) Significantly Reduces the Risk of Disease Worsening or Death in Patients with BRCA-Mutated Metastatic Breast Cancer

Business Wire June 4, 2017

Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi

PR Newswire June 1, 2017

Tracking The Busy June PDUFA Calendar

Benzinga.com May 30, 2017

AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 26, 2017

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

Business Wire May 25, 2017